STOCK MARKET BSE NSE

Pennsylvania jury directs Johnson & Johnson to pay USD 8 billion over drug side effect

The company challenged the ruling in a statement, calling the damages awarded "grossly disproportionate" with the initial award in the case of USD 680,000. 

Published: 09th October 2019 12:44 PM  |   Last Updated: 09th October 2019 12:44 PM   |  A+A-

Johnson & Johnson company is facing a series of complaints in state courts for failing to properly warn of Risperdal's side effects. (Photo | PTI)

By AFP

A Pennsylvania jury ruled Tuesday that US pharmaceutical giant Johnson & Johnson must pay $8 billion in damages and interest for failing to warn that a psychiatric drug could cause breast growth in men.  

Johnson & Johnson and its subsidiary Janssen Pharmaceuticals were blamed as plaintiff Nicholas Murray told the Philadelphia court that the drug Risperdal, prescribed to treat schizophrenia and bipolar disorder, had made him grow breasts. 

The company challenged the ruling in a statement, calling the damages awarded "grossly disproportionate" with the initial award in the case of $680,000. 

"The company is confident (the ruling) will be overturned," the statement said, and "will be immediately moving to set aside this excessive and unfounded verdict." 

In the statement, Johnson & Johnson accused the court of preventing their defense team from presenting "key evidence" on Risperdal labeling. 

The company is facing a series of complaints in state courts for failing to properly warn of Risperdal's side effects, including in Pennsylvania, California and Missouri.  

Risperdal, approved for the treatment of adults by the US Food and Drug Administration in 1993, brought in some $737 million (672 million euros) in sales in 2018. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp